Clinical Trial Update: A Study of LJPC-501 in Pediatric Patients With Hypotension [Phase 2]

View source ↗

Summary

Phase 2 trial update for LJPC-501 in pediatric patients with catecholamine-resistant hypotension completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholamine-resistant Hypotension
• Distributive Shock
• High-output Shock
• Sepsis

Drugs mentioned

• LJPC-501

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 2 | Status: COMPLETED